🚨 Cardiogenic Shock—A Decade Later
The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone.
📉 Mortality: 52.5% vs 68.8% (HR 0.70)
🛠️ Despite higher adverse events, the survival benefit endured a full decade.
📊 This changes how we think about long-term outcomes in mechanical support.
🔗 Time to revisit your shock protocols?
#DanGerShock #Impella #CardiogenicShock #STEMI #LongTermOutcomes #NEJM #MCS #Cardiology #SurvivalBenefit #ImpellaCP
